With the increasing age of patients undergoing allogeneic hematopoietic cell transplantation (HCT), the age of matched related sibling donors (MRDs) is expected to increase. Donor safety and the impact of donors' age on mobilization, collection of peripheral hematopoietic progenitor cells (HPCs), subsequent engraftment and the incidence of GVHD were retrospectively analyzed. A total of 167 patients received HCT from an MRD. Median donors' age was 48 years (67 (40%) donors were X50 years including 34 donors X60 years). Side effects under mobilization and apheresis were age independent. Grafts from donors o50 years contained more CD34 þ cells (median 9 Â 10 6 /kg recipient's body weight (RBW)) compared with older donors (median 5.9 Â 10 6 /kg RBW) (Po0.0005), whereas harvests from donors X60 years contained more natural killer (NK) cells (P ¼ 0.003). Engraftment occurred at a median of 12 days after HCT irrespective of donors' age. Increasing age of MRD did not preclude successful mobilization, collection of HPC and engraftment. In the context of more NK cells in grafts from elderly donors, the impact of donors' age on outcome after HCT warrants further studies. Although short-term toxicities of apheresis were not increased with increasing age, long-term donor safety remains an important issue.
Introduction
Of the three possibilities of procurement of hematopoietic progenitor cells (HPCs), namely BM, granulocyte colonystimulating factor mobilized peripheral blood and cord blood; peripheral blood is the predominant source of HPC in Europe. 1 Harvesting HPC is feasible, convenient and the risk for the donor is generally considered minimal. [2] [3] [4] [5] If available, an HLA-identical sibling is usually the source of HPC for patients requiring an allogeneic hematopoietic cell transplantation (HCT). Several studies are available comparing the outcome of HCT from an HLA-identical sibling wherein peripheral blood is the source of HPC with that following a BM harvest. [6] [7] [8] [9] [10] [11] [12] Over the last years, reduced intensity conditioning (RIC) has enriched the treatment possibilities for elderly patients whose disease could be cured with HCT. The frequencies of RIC HCT have risen from less than 1% of all allogeneic HCT in 1998 to 34% in 2006. 13 Consequently, an HLA-identical sibling above the age of 60 years is expected to be encountered more frequently. Paradoxically, only very limited data exist regarding the impact of increasing donor age on peripheral blood mobilization, quality of HPC harvested and subsequent engraftment, and incidence of GVHD in the recipient.
We retrospectively analyzed donors' safety and the impact of the age of matched related sibling donor (MRD) on mobilization and collection of HPC, as well as on subsequent engraftment and GVHD in 167 recipients of HCT at the University of Leipzig.
Patients and methods
A total of 167 consecutive patients (72 (43%) females, and 95 (57%) males) who received HCT from a MRD at the University of Leipzig from January 2000-January 2006 were retrospectively analyzed. HPC source was peripheral blood in all patients. Informed consent was obtained from both patients and donors.
Patient characteristics
Median age was 48 (range 18-74) years. Diagnoses were acute leukemia (n ¼ 67 (40%)), chronic leukemia (n ¼ 37 (22%)), multiple myeloma (n ¼ 24 (14%)), myelodysplastic syndrome (n ¼ 13 (8%)) and others (n ¼ 26 (16%)). Conventional conditioning with 12 gray TBI and CY 60 mg/kg body weight daily i.v. on days 1 and 2 (total dose 120 mg/kg) was given to 79 (47.3%) patients below 55 years of age.
For older patients (n ¼ 88 (52.7%)), RIC (fludarabine 30 mg/m 2 daily i.v. for 3 days and two gray TBI once, followed by immunosuppression with CYA (through level X200 ng/ml) and mycophenolate mofetil) was applied. Donor work-up included detailed information about the procedure and potential risks, obtaining a signed informed consent, thorough clinical and laboratory evaluation, an electrocardiogram, ultrasound examination of the abdomen, chest X-ray and BM examination. A history of hypertension was recorded in 92 (55%) of the donors, and 56 (33.5%) donors had a history of drug treatment. Further relevant medical events, which did not preclude donation, were captured 26 times (diabetes mellitus, n ¼ 9; chronic bronchitis, n ¼ 6; history of venous thrombosis, n ¼ 5; and history of cardiac disease, n ¼ 6). Table 1 shows patient and donor characteristics.
Donor characteristics

Mobilization and harvest of HPC
Harvesting of HPC was made by leukapheresis after treatment with filgrastim 5 mg/kg body weight, applied subcutaneously twice daily starting on day À4 of the apheresis. In only 9 (5.4%) donors (o50 years, n ¼ 6 and X50 years, n ¼ 3), peripheral veins were not considered adequate and a central venous line was required for apheresis. On the morning of the scheduled apheresis, donor peripheral blood CD34 þ cells were measured and apheresis started, if the count was X1 Â 10 7 /L using the COBE Spectra Apheresis System (CaridianBCT Inc., Lakewood, CO, USA). The volume of the harvest and the counts for total mononuclear cells, T cells (CD3 þ ), CD34 þ cells and natural killer (NK) (CD3À/CD56 þ ) cells were measured. If the target of X3 Â 10 6 / kg recipient's body weight (RBW) CD34 þ cell count was not achieved by one apheresis, the procedure was repeated the next day after administration of two further injections of filgrastim 5 mg/kg body weight. The cells in all peripheral blood samples and HPC products were sorted by flowcytometricactivated cell sorting using the FACSCalibur Flow Cytometer (BD Biosciences, San Jose, CA, USA) and measured as previously described. 14 Chimerism analyses in the recipient after RIC HCT For patients receiving RIC HCT, donor chimerism in the recipient was analyzed in unsorted BM cells, flow-sorted T and CD34 þ marrow cells on day 28 after HCT by fluorescence in situ hybridization for the XY chromosome in gender mismatched or PCR-based analysis of polymorphic microsatellite regions in gender-matched HCT. 15 Safety assessment during mobilization and harvest of PBSC All donors were mobilized as inpatients with daily clinical and laboratory assessment during mobilization, during and following apheresis. Laboratory assessment included a blood count, liver function tests (alanine aminotransferase, aspartate aminotransferase, alkaline phosphates and bilirubin), creatinine, lactate dehydrogenase, prothrombin time, partial thromboplastin time and potassium. In addition, all donors had a clinical and laboratory evaluation 1 week, 1 month and 1 year after apheresis.
The National Cancer Institute Common Toxicity Criteria Version 2.0 were used for assessment of hematological and non-hematological side effects. (n ¼ 100) vs the older donors (n ¼ 67) and those below 60 years of age (n ¼ 133) vs 60 years old and above (n ¼ 34). Statistical analysis was performed by SPSS 15.0 of Windows software package (SPSS, Chicago, IL, USA).
Statistical analysis
Results
Mobilization and harvest of HPC Mobilization was successful, with adequate harvests collected in all donors after a median of one (range 1-3) apheresis. In 148 (89%) donors, the target of X3 Â 10 6 / kg RBW CD34 þ cell count was achieved by one apheresis after a median of 22 (range 10-65) L of blood processed during apheresis. Only five (3%) donors required three sessions. With the exception of one donor where 2.8 Â 10 6 / kg RBW CD34 þ cells were collected, all grafts contained X3 Â 10 6 /kg RBW CD34 þ cells. In univariate analysis, donors X60 years tended to need more sessions (P ¼ 0.07) and a larger volume of blood processed during apheresis (median 24 L) compared with younger patients with a median of 22 L to yield the target CD34 þ cell count (P ¼ 0.09) but this was not significant in multivariate analysis (P ¼ 0.9).
There was a strong negative association between the age of the donor and peripheral blood CD34 þ cell count before apheresis in both univariate (Po0.0005) and multivariate analyses (P ¼ 0.01). Donors below 50 years had significantly higher counts (median 7. Table 2 summarizes the impact of donors' age on mobilization and harvest of HPC.
Engraftment and donor chimerism in the recipient As expected, in both uni-and multivariate analyses, recipients of transplants from donors X50 years of age were significantly older and were offered more often RIC compared with recipients of grafts obtained from younger donors (Po0.0005).
All patients engrafted with WBC count X1 Â 10 9 /L on two consecutive days sustained platelet counts X50 Â 10 9 /L without platelet transfusions observed after a median of 12 (range 0-37) and 12 (range 0-63) days after HCT respectively. Although in univariate analysis, conventional conditioning (P ¼ 0.004), younger patient and donor ages (P ¼ 0.02), and lower CD34 þ cell count in the harvest (P ¼ 0.01) were associated with a slower WBC recovery, in multivariate analysis, only conventional conditioning compared with RIC remained associated with a slower WBC recovery (P ¼ 0.005). Regarding platelet recovery, only a lower CD34 þ cell count in the harvest was significantly associated with a slower recovery in multivariate analysis (P ¼ 0.008). NK-cell count in the graft had no impact on WBC (P ¼ 0.4) or platelet (P ¼ 0.3) recovery. After RIC HCT, median donor chimerism in unsorted marrow cells, CD3 þ and CD34 þ cells on day 28 after HCT were 94 (range 22-100), 77 (range 10-100) and 99 (range 4-100) %, respectively, and were not influenced by the number of NK cells in the graft. Only in univariate analysis, donor age X60 years was associated with a lower total and CD3 þ cell but not CD34 þ cell donor chimerism in the recipient.
GVHD
Overall incidence of acute and chronic GVHD were 90/167 (53.9%) and 62/139 (44.6%), respectively (Table 3) . Acute GVHD was seen more often in patients below 50 years compared with older patients (P ¼ 0.007). This was mainly because a significantly higher incidence of cutaneous GVHD stages 1 and 2.
On the other hand, no correlation was found between older age and chronic GVHD, although patients X60 years tended to suffer more often from chronic cutaneous GVHD in comparison with younger patients (P ¼ 0.02).
Interestingly, no association could be found between donor age or NK-cell count in the transplant and the incidence or severity of both acute and chronic GVHD.
Side effects of mobilization and harvest of HPC
In general, all donors, irrespective of age, tolerated mobilization and apheresis well. There were no complications related to placement of central venous line in the nine donors who required a central line for apheresis. No differences were noted in median Hb, WBC and platelet counts before mobilization in regard to age. On the other hand, donors X50 years of age tended to have significant lower WBC counts before apheresis compared with younger patients.
Although donors X50 years of age tended to have lower platelet counts after apheresis in univariate analysis (P ¼ 0.02), this was not significant in multivariate analysis (P ¼ 0.2). The degree of thrombocytopenia under apheresis and platelet recovery thereafter was not influenced by age. No bleeding episode was encountered in the entire cohort (Table 2) .
Under mobilization and apheresis, 129 (77%) donors experienced no symptoms. Bone pain was reported in 38 (23%) donors, which was greater than grade 2 in seven (4.2%) donors.
No greater than grade 2 alanine aminotransferase, aspartate aminotransferase, bilirubin, creatinine, fibrinogen, lactate dehydrogenase or prothrombin time toxicities were detected. Reversible alkaline phosphate elevation was noted in 106 (63.5%) (grade 1 in 49, grade 2 in 46, and grade 3 in 11) donors.
After apheresis, a prolonged partial thromboplastin time was seen in 56 (33.5%) (grade 1 in 45, grade 2 in 8, grade 3 in 1 and grade IV in 2) donors. Partial thromboplastin time normalized spontaneously in all donors within 4-6 h after apheresis. Also hypokalemia successfully managed with oral potassium was observed in 74 (44.3%) (grade 1 in 35, grade 2 in 35 and grade 3 in 4) donors. Elderly donors did not witness more toxicities compared with younger donors. Regarding alkaline phosphate, age o60 years was clearly associated with more alkaline phosphate elevations in both uni-and multivariate analyses. Table 2 summarizes the impact of the age of the donor on hematological and non-hematological toxicities under mobilization and harvest of HPC.
Second mobilization and harvest of HPC From the whole cohort of donors, 24 (13.6%). underwent a second mobilization and collection of HPC after a median of 256 (range 89-1589) days following the first donation because of relapse of the underlying disease in the recipient. Median age of patients and donors were 51 (range 18-68) and 46 (21-68) years, respectively. Eight (33.3%) donors were X50 years old. Similar to the first apheresis, the second donation was successful and without significant side effects in all donors irrespective of age.
Discussion
Granulocyte colony-stimulating factor-mobilized peripheral blood is feasible, convenient and considered the predominant source of stem cells. [1] [2] [3] [4] [5] It is inevitable that the increasing frequency of patients who are offered RIC HCT, mainly because of advanced age, would be accompanied by an increasing number of elderly matched sibling donors. Only very limited data exist regarding the impact of an increasing donor age on the feasibility and quality of mobilization and harvest of HPC, as well as subsequent engraftment and GVHD in the recipient. In a recent publication, Tempescul et al. showed that in the setting of autologous HCT, patients older than 65 years with myeloma or lymphoma could also undergo HPC harvests similar to younger patients, with the majority of patients only needing one apheresis (71%). 16 On the other hand, an inverse correlation between the pre-apheresis CD34 þ cell count and age in related donors stimulated with lenograstim has been published. 17 Our data demonstrate clearly that increasing age of identical siblings deemed fit for donation does not preclude successful mobilization and collection of HPC. Although donors younger than 50 years mobilized more efficiently as reflected in a higher median peripheral blood CD34 þ cell count before collection and a higher median CD34 þ cell count in the harvests compared with older donors, nevertheless transplants from all donors, Table 3 Acute and chronic GVHD Parameter Acute GVHD, irrespective of age, contained sufficient HPC and T lymphocytes required for successful engraftment. An interesting observation was the strong positive correlation of NK-cell counts in the harvests and the age of the donor. The older the donor, the more NK cells were collected in our cohort. NK cells, the first lymphocyte subset to reconstitute the peripheral blood after allogeneic HCT, [18] [19] [20] have been implicated in the suppression of GVHD, the promotion of engraftment and the mediation of a GVL effect. [21] [22] [23] [24] [25] [26] [27] [28] Mediators of the inhibitory signals for NK-cell activity include the inhibitory killer Ig-like receptors (KIRs), many of which are known to have differential ligand specificities for HLA class I molecules. Upon interaction with target cells lacking HLA ligand, inhibitory KIR-expressing NK cells may have a lowered threshold for activation, particularly if target cells express additional activating NK receptor ligands. 21, 22 When exerted in the donor-vs-recipient direction, NK-cell alloreactivity emerged as a crucial factor in improving outcome of haploidentical transplantation, with alloreactive clones detectable in vivo in recipients for up to 1 year after transplant. 29 Also, in HLA-identical sibling transplantations, Hsu et al. demonstrated by analyzing donor KIR genotype with HLA genotype that 62.9% of the patients lacked an HLA ligand for donor-inhibitory KIR. Their data suggest that the absence of class I ligand in the recipient for donor-inhibitory KIR can contribute to improved outcome for patients with AML and MDS. 30 In our study, higher NK-cell count in the transplant was not associated with a higher incidence of GVHD or with delayed engraftment. Nevertheless, the influence of the number of transfused NK cells with or without NK-cell alloreactivity on outcome after allogeneic HCT is an interesting and challenging aspect to be addressed in future clinical studies.
Another positive observation was the fact that advanced donor age was not associated with an increased incidence of acute and chronic GVHD in the recipient.
Also, there was no increased incidence in hematological or non-hematological toxicities with increasing donor age during mobilization, collection of HPC and no serious adverse events were reported in the first year after donation.
Nevertheless, a few points need to be addressed. Although the risk for the donor is generally considered minimal, there is a small but definite risk of serious adverse events and fatalities. Additionally, experimental data and observational reports raised concern about an elevated risk of hematologic malignancies after granulocyte colonystimulating factors administration. 31, 32 In a recent survey conducted by the European Group for Blood and Marrow Transplantation (EBMT) including 23 254 donors of peripheral HPC four fatalities (incidence 0.98 per 10 000 donations; 95% confidence interval 0.32-2.29), 25 severe adverse events (10.76/10,000; 95% confidence interval 6.97-15.85) and 12 hematologic malignancies were reported. The calculated incidence of hematologic malignancies of 1.20 per 10 000 person-years of follow-up did not exceed the expected incidence in an ageand sex-adjusted general population. 5 In our cohort, the median age of donors was 47 years, with 40% of donors being X50 years old compared with a median of 43.7 years for related donors of peripheral HPC in the EBMT survey. It is expected that with the increasing age of the recipients of HCT, the number of older family donors with comorbidities will continue to increase.
Further, true incidences of long-term complications might be higher as reported because lack of standardized donor follow-up and underreporting of data from donors whose recipients died.
So, donors must be informed about the potential risks of donation, systematic follow-up of donors established and serious adverse captured in prospective studies.
Implementing the Joint Accreditation Committee-ISCT & EBMT (JACIE), accreditation standards have led to significant improvements in different aspects of transplant programs including donor and collection issues. 33 In conclusion, an increasing age of matched related siblings does not preclude successful mobilization and collection of HPC, and seems to have no negative impact on both subsequent engraftment and the incidence of acute as well as chronic GVHD in the recipient. For the first time, we describe a higher NK-cell count encountered in grafts from elderly donors. The age of the donor as a possible donor-related factor possibly influencing outcome after HCT needs to be further evaluated. In the era of older family donors with possible comorbidities, long-term safety after donation becomes even more important than ever before.
